[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting]. / Novaia lekarstvennaia forma ondansetrona (zofrana)--lingval'nye tabletki v preduprezhdenii vroty, toshnoty i narushenii appetita, indutsiruemykh tsitostatikami.

Ondanserton (zofran), 16-32 mg/24 hr, lingual tablets, 2 days, was administered in 40 patients with advanced tumors who received combination chemotherapy (ABVD) (9 patients with Hodgkin's disease), CHOP (16--non-Hodgkin's lymphoma), gemzar + cisplatin (6--ovarian and 5--breast cancer), CAF, AC and taxol + carboplatin) (4). Distinct prophylactic antiemetic effect, delayed effect (94%) included, was reported in the CHOP group: full control--64% and partial control in gemzar + cisplatin treatment (27%). Loss of appetite was prevented in most patients receiving CHOP and gemzar + cisplatin. Untoward side-effects of ondansetron were not registered.

[Therapeutic potential of Granisetron (Kitryl) for the prevention of nausea and vomiting induced by cytostatic drugs]. / Vozmozhnosti primeneniia Granisetrona (Kitrila) dlia preduprezhdeniia rvoty i toshnoty, vyzvannoi tsitostatikami.

Oral administration of 2 mg kitryl effectively controlled nausea (82.5-96.7%) and vomiting (97.3-99.1%) induced in 127 patients with malignant lymphomas and solid tumors, who received highly emetic cytostatic MOPP, ABVD, CHOP, CHOEP, EVAP, VP and CMP therapy. The antiemetic effect of oral administration was identical to that of intravenous injection of 3 mg.

[The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy]. / Fludarabina fosfat (Fludara) v lechenii reziztentnykh k standartnoi khimioterapii bol'nykh B-kletochnym khronicheskim limfoleikozom i nekhodzhkinskimi limfomami.

Following monochemotherapy with fludarabin phosphate (fludara), complete (18%), and partial remission (27%) with stabilization (45%) was recorded in patients with B-cell chronic lymphocytic leukemia, most of whom were resistant to alkylating cytostatic drugs and their combinations containing anthracyclines. Long-term remission was registered in patients with low and moderate grade non-Hodgkin's lymphoma, resistant to standard cytostatic treatment, due to the therapeutic synergism of fludara and cytosinarabinoside (FAVAMP).